Esteghamat N, Tsumura A, Marquez-Arreguin G, Tuscano J
Front Oncol. 2024; 14:1481950.
PMID: 39502312
PMC: 11534736.
DOI: 10.3389/fonc.2024.1481950.
Moyo T, Vaidya R
Front Oncol. 2024; 14:1397186.
PMID: 39211553
PMC: 11357917.
DOI: 10.3389/fonc.2024.1397186.
Braunstein Z, Ruiz M, Hanel W, Shindiapina P, Reneau J, Brammer J
J Pers Med. 2022; 12(6).
PMID: 35743749
PMC: 9225101.
DOI: 10.3390/jpm12060964.
Munshi P, Chen Y, Ahn K, Awan F, Cashen A, Shouse G
Transplant Cell Ther. 2022; 28(8):487.e1-487.e7.
PMID: 35609865
PMC: 9375438.
DOI: 10.1016/j.jtct.2022.05.029.
Dahi P, Lee J, Devlin S, Ruiz J, Maloy M, Rondon-Clavo C
Blood Adv. 2021; 5(12):2608-2618.
PMID: 34152404
PMC: 8270665.
DOI: 10.1182/bloodadvances.2020004167.
Dose-adjusted high-dose chemotherapy with autologous stem cell transplantation for elderly (≥ 70 years old) lymphoma patients.
Hosoi H, Murata S, Mushino T, Tamura S, Sonoki T
Ann Hematol. 2021; 101(1):205-207.
PMID: 33404691
DOI: 10.1007/s00277-020-04373-z.
Long-term outcomes of older patients with relapsed/refractory NHL referred to ASCT.
Pytlik R, Vackova B, Konirova E, Trnkova M, Blahovcova P, Pohlreich D
Bone Marrow Transplant. 2020; 56(3):709-712.
PMID: 32884117
DOI: 10.1038/s41409-020-01045-4.
Outcome after autologous stem cell transplantation in primary refractory or relapsed Hodgkin lymphoma-a long-term follow-up single center experience.
Roerden M, Sokler M, Kanz L, Bethge W, Vogel W, Walz J
Ann Hematol. 2020; 99(2):265-276.
PMID: 31897675
DOI: 10.1007/s00277-019-03900-x.
Delivering intensive therapies to older adults with hematologic malignancies: strategies to personalize care.
Olin R
Hematology Am Soc Hematol Educ Program. 2019; 2019(1):63-70.
PMID: 31808886
PMC: 6913447.
DOI: 10.1182/hematology.2019001300.
Autologous Stem Cell Transplantation in Elderly Lymphoma Patients in Their 70s: Outcomes and Analysis.
Sun L, Li S, El-Jawahri A, Armand P, Dey B, Fisher D
Oncologist. 2017; 23(5):624-630.
PMID: 29284757
PMC: 5947447.
DOI: 10.1634/theoncologist.2017-0499.
High-dose thiotepa-based chemotherapy with autologous stem cell support in elderly patients with primary central nervous system lymphoma: a European retrospective study.
Schorb E, Fox C, Fritsch K, Isbell L, Neubauer A, Tzalavras A
Bone Marrow Transplant. 2017; 52(8):1113-1119.
PMID: 28436974
DOI: 10.1038/bmt.2017.23.
Surgery for Non-Hodgkin's Lymphoma.
Weledji E, Enow Orock G
Oncol Rev. 2016; 9(1):274.
PMID: 26779310
PMC: 4698592.
DOI: 10.4081/oncol.2015.274.
High dose therapy and autologous hematopoietic stem cell transplantation in septuagenarians with non-Hodgkin lymphoma: Feasible, but for which patients?.
Wildes T, Cashen A
J Geriatr Oncol. 2015; 6(5):344-5.
PMID: 26272671
PMC: 4813505.
DOI: 10.1016/j.jgo.2015.07.001.
High-Dose Chemotherapy and Autologous Stem Cell Transplant in Older Patients with Lymphoma.
Lahoud O, Sauter C, Hamlin P, Dahi P
Curr Oncol Rep. 2015; 17(9):42.
PMID: 26201264
PMC: 5542393.
DOI: 10.1007/s11912-015-0465-x.
Myeloablative I-131-tositumomab with escalating doses of fludarabine and autologous hematopoietic transplantation for adults age ≥ 60 years with B cell lymphoma.
Gopal A, Gooley T, Rajendran J, Pagel J, Fisher D, Maloney D
Biol Blood Marrow Transplant. 2014; 20(6):770-5.
PMID: 24530971
PMC: 4019701.
DOI: 10.1016/j.bbmt.2014.02.004.
Hematopoietic stem cell transplantation for hematologic malignancies in older adults: geriatric principles in the transplant clinic.
Wildes T, Stirewalt D, Medeiros B, Hurria A
J Natl Compr Canc Netw. 2014; 12(1):128-36.
PMID: 24453296
PMC: 4010196.
DOI: 10.6004/jnccn.2014.0010.
